BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 10,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total transaction of $156,700.00. Following the completion of the transaction, the chief marketing officer now directly owns 129,644 shares of the company’s stock, valued at approximately $2,031,521.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Todd Berard also recently made the following trade(s):

• On Wednesday, March 27th, Todd Berard sold 515 shares of BioLife Solutions stock. The stock was sold at an average price of $17.99, for a total transaction of $9,264.85.
• On Monday, March 11th, Todd Berard sold 401 shares of BioLife Solutions stock. The stock was sold at an average price of $17.42, for a total transaction of $6,985.42.
• On Wednesday, February 21st, Todd Berard sold 111 shares of BioLife Solutions stock. The stock was sold at an average price of $17.35, for a total transaction of $1,925.85.
• On Friday, January 19th, Todd Berard sold 1,232 shares of BioLife Solutions stock. The stock was sold at an average price of $16.76, for a total transaction of $20,648.32.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $15.86 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. BioLife Solutions, Inc. has a 1-year low of $8.92 and a 1-year high of $24.50. The firm has a market capitalization of $718.46 million, a P/E ratio of -10.43 and a beta of 1.67. The company’s 50-day moving average is $17.44 and its 200 day moving average is $15.34.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. Research analysts forecast that BioLife Solutions, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

Separately, Jefferies Financial Group assumed coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $23.40.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. Nisa Investment Advisors LLC raised its position in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 1,020 shares during the period. Point72 Hong Kong Ltd bought a new position in BioLife Solutions in the 1st quarter worth about $36,000. Cubist Systematic Strategies LLC bought a new position in BioLife Solutions in the 1st quarter worth about $36,000. GAMMA Investing LLC bought a new position in BioLife Solutions in the 4th quarter worth about $41,000. Finally, US Bancorp DE grew its stake in BioLife Solutions by 374.6% in the 4th quarter. US Bancorp DE now owns 2,520 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 1,989 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.